Drug-induced cardiotoxicity is the leading cause of both drug development failures and market withdraw or restriction. Compounds that exert cardiovascular toxicity, no matter acute or subtle effect, can lead to severe adverse consequences, such as arrhythmia, myocardium structural damage, and even sudden death. Therefore, a comprehensive survey of cardiac safety represents a high priority for IND submissions as well as a crucial step to prevent later stage failures.https://www.creative-biolabs.com/drug-discovery/therapeutics/cardiotoxicity.htm
